Epidemiology of Disseminated Sclerosis

McMenemey, W. H.; Allison, R. S.

doi:10.1177/003591576105400101

Cited by 11 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple sclerosis (MS) is a neurodegenerative disease, which is characterized with chronic demyelinating pathological changes of the central nervous system (CNS). Since its discovery, the morbidity of this disease steadily increases according to previous reports. − Because MS is a demyelinating disease of the CNS, its typical manifestation would be abnormal neurological signs, including sensory deficit symptoms such as visual field disturbance, pain of eye movement, double and blurred vision, loss of sensation on the face or extremities, and motor symptoms such as weakness of the face and extremities that may further lead to the development of paraparesis and paraplegia. − In a study conducted by Benoit et al, they found that the median age of MS patients who develop an irreversible disability with a score of the Krtzke Disability Status Scale (DSS) 4 (patients with limited walking but with no aid) is 44.3 years old, while being 54.7 years old for DSS 6 (patients walking with unilateral walking aid) and 63.1 years old for DSS 7 (wheelchair-bound patients), demonstrating how MS could greatly affect the prognosis and life quality of patients. In fact, many reports and studies have concluded that the influence of MS-related disability on life quality is greater than any other causes of disabilities and MS has generated a severe disease burden worldwide with a high productivity-loss cost resulting from the MS disability. − …”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Nanomedicines for Multiple Sclerosis Therapy

Zeng

et al. 2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neurological disorder characterized by loss of the myelin sheath. Since the myelin sheath could insulate nerve fibers from the surrounding environment, its loss would result in dysfunction of the affected neurons in transmitting electrical signals, thus leading to sensation and motor disabilities. The treatment of MS is accompanied by a low treatment efficacy due to the existence of the blood−brain barrier (BBB) and occurrence of side effects due to a poor targeting efficacy. To overcome these obstacles of traditional MS treatment methods, nanomedicines have recently been employed to deliver MS therapeutic agents to the lesions. With deep BBB penetration and specific targeting, these nano-based interventions have received positively encouraging results and become another potential MS treatment method with better therapeutic outcomes. This review will focus on recent advances in nanomedicines for the treatment of MS by critically analyzing their strengths and weaknesses. We will propose perspectives on the development of these MS therapeutic nanomaterials.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Advances in Nanomedicines for Multiple Sclerosis Therapy

Zeng

et al. 2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

Anxiety

Hall

1980

Psychiatric Presentations of Medical Illness

View full text Add to dashboard Cite

Recent advances in development of nanomedicines for multiple sclerosis diagnosis

Zhang¹,

Dai²,

Hu³

et al. 2021

Biomed. Mater.

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neurodegenerative disease with a high morbidity and disease burden. It is characterized by the loss of the myelin sheath, resulting in the disruption of neuron electrical signal transmissions and sensory and motor ability deficits. The diagnosis of MS is crucial to its management, but the diagnostic sensitivity and specificity are always a challenge. To overcome this challenge, nanomedicines have recently been employed to aid the diagnosis of MS with an improved diagnostic efficacy. Advances in nanomedicine-based contrast agents in magnetic resonance imaging scanning of MS lesions, and nanomedicine-derived sensors for detecting biomarkers in the cerebrospinal fluid biopsy, or analyzing the composition of exhaled breath gas, have demonstrated the potential of using nanomedicines in the accurate diagnosis of MS. This review aims to provide an overview of recent advances in the application of nanomedicines for the diagnosis of MS and concludes with perspectives of using nanomedicines for the development of safe and effective MS diagnostic nanotools.

show abstract

Epidemiology of Disseminated Sclerosis

Cited by 11 publications

References 11 publications

Recent Advances in Nanomedicines for Multiple Sclerosis Therapy

Recent Advances in Nanomedicines for Multiple Sclerosis Therapy

Anxiety

Recent advances in development of nanomedicines for multiple sclerosis diagnosis

Contact Info

Product

Resources

About